Advantech Capital Ii Investment Partners Limited - Net Worth and Insider Trading

Advantech Capital Ii Investment Partners Limited Net Worth

The estimated net worth of Advantech Capital Ii Investment Partners Limited is at least $191 Million dollars as of 2024-11-07. Advantech Capital Ii Investment Partners Limited is the of Alphamab Oncology and owns about 49,424,035 shares of Alphamab Oncology (HKSE:09966) stock worth over $191 Million. Details can be seen in Advantech Capital Ii Investment Partners Limited's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Advantech Capital Ii Investment Partners Limited has not made any transactions after 2019-12-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Advantech Capital Ii Investment Partners Limited

Advantech Capital Ii Investment Partners Limited Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Advantech Capital Ii Investment Partners Limited owns 1 companies in total, including Alphamab Oncology (HKSE:09966) .

Click here to see the complete history of Advantech Capital Ii Investment Partners Limited’s form 4 insider trades.

Insider Ownership Summary of Advantech Capital Ii Investment Partners Limited

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:09966	Alphamab Oncology	2019-12-12

Advantech Capital Ii Investment Partners Limited Latest Holdings Summary

Advantech Capital Ii Investment Partners Limited currently owns a total of 1 stock. Advantech Capital Ii Investment Partners Limited owns 49,424,035 shares of Alphamab Oncology (HKSE:09966) as of December 12, 2019, with a value of $191 Million.

Latest Holdings of Advantech Capital Ii Investment Partners Limited

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:09966	Alphamab Oncology	2019-12-12	49,424,035	3.87	191,271,015

Holding Weightings of Advantech Capital Ii Investment Partners Limited

Advantech Capital Ii Investment Partners Limited Form 4 Trading Tracker

According to the SEC Form 4 filings, Advantech Capital Ii Investment Partners Limited has made a total of 1 transactions in Alphamab Oncology (HKSE:09966) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Alphamab Oncology is the sale of 0 shares on December 12, 2019, which brought Advantech Capital Ii Investment Partners Limited around $0.

Insider Trading History of Advantech Capital Ii Investment Partners Limited

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Advantech Capital Ii Investment Partners Limited Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Advantech Capital Ii Investment Partners Limited Ownership Network

Ownership Network List of Advantech Capital Ii Investment Partners Limited

No Data

Ownership Network Relation of Advantech Capital Ii Investment Partners Limited

Advantech Capital Ii Investment Partners Limited Owned Company Details

What does Alphamab Oncology do?

Who are the key executives at Alphamab Oncology?

Advantech Capital Ii Investment Partners Limited is the of Alphamab Oncology. Other key executives at Alphamab Oncology include 2301 Trustee South Dakota Trust Company Llc , 2305 Beneficiary of a trust Xu Ting , and 2307 Founder of a discretionary trust who can infl LIU YANG .

Alphamab Oncology (HKSE:09966) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alphamab Oncology (HKSE:09966) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alphamab Oncology (HKSE:09966) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alphamab Oncology (HKSE:09966)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alphamab Oncology Insider Transactions

No Available Data

Advantech Capital Ii Investment Partners Limited Mailing Address

Above is the net worth, insider trading, and ownership report for Advantech Capital Ii Investment Partners Limited. Currently GuruFocus does not have mailing address information for Advantech Capital Ii Investment Partners Limited.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.